Short answer
Organogenesis Holdings Inc. (ORGO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $45M (down 69.9% year over year) with net income of −$30M.
Q3 2026 key financials · XBRL
- Revenue
- $45M
- −69.9% YoY · +3.9% QoQ
- Net income
- −$30M
- −237.4% YoY · +69.2% QoQ
- Operating margin
- -64.9%
- EPS (diluted)
- −$0.26
- −273.3% YoY · +66.2% QoQ
Source: XBRL data from the Organogenesis Holdings Inc. (ORGO) Q3 2026 10-Q on SEC EDGAR. USD.
Organogenesis Holdings Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $45.5M, down 70% YoY from $150.9M, driven by Advanced Wound Care disruption
- Gross margin 51.8% vs 75.8% YoY, reflecting Medicare reimbursement changes and product mix
- Advanced Wound Care revenue $38.2M, down 73%; Surgical & Sports Medicine $7.3M, down 19%
- Cash $21.3M at September 30; operating cash use $29.1M through nine months
- Management expects significant YoY revenue declines in fourth quarter amid reimbursement headwinds and clinician confusion
Risk Factors
- New capital-raising risk: declining cash, reduced product revenue, and Revolving Facility expiration on August 6, 2026
- Liquidity risk: $75.0 million ATM capacity may remain inaccessible because it is not committed financing
- Market risk: revenue disruption followed LCD coverage-policy withdrawal and CMS discarded-product comments
- Shareholder dilution risk: future equity or convertible-debt financing could dilute existing stockholders
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Organogenesis Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.